Accelerated Approval vs Traditional Pathways
Accelerated Approval vs Traditional Pathways Decoding Accelerated vs Traditional Approval Pathways in Rare Disease Drug Development Understanding the Regulatory Landscape for Rare Disease Therapies Developing drugs for rare diseases involves a unique set of regulatory considerations. Given the limited patient populations and the often life-threatening nature of these conditions, regulatory agencies like the U.S. Food…